论文部分内容阅读
目的:总结1例地西他滨治疗急性巨核细胞白血病(AML-M7)的诊疗体会。方法:对1例AML-M7患者用达珂20mg.m-2.d-1×8d诱导治疗。结果:达珂5d诱导治疗结束后,骨髓形态学示原始细胞由初诊时的48%降至16%,巨核细胞由500个/片,降为7个/片。加用达珂20mg.m-2.d-1×3d,治疗结束后35d复查骨穿示:M7骨髓象完全缓解。结论:地西他滨对于AML-M7可能是值得探索的有效治疗药物。
Objective: To summarize the experience of treating and treating acute megakaryocyte leukemia (AML-M7) in 1 case of decitabine. Methods: One patient with AML-M7 was induced with Dacron 20mg.m-2.d-1 × 8d. Results: After 5 days induction of Dacron, the morphology of bone marrow showed that the number of blasts decreased from 48% to 16% at the initial diagnosis, and the number of megakaryocytes decreased from 500 to 7 pieces per piece. Addition with Da Ke 20mg.m-2.d-1 × 3d, 35d after the end of treatment review bone wear: M7 bone marrow completely relieved. Conclusion: Decitabine may be an effective therapeutic for AML-M7.